Date

Presenter

Title/paper

Objectives

August 19, 2025

Dr. Stephanie Pomeroy

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.

https://www.nejm.org/doi/10.1056/NEJMoa2403614

• To discuss the efficacy of Amivantamab-Lazertinib
• To discuss the safety of Amivantamab-Lazertinib
• To discuss the applicability of this study in our province/patient population

Dr. Melanie Seal

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer

https://qe2a-proxy.mun.ca/Login?url=https://www.nejm.org/doi/10.1056/NEJMoa2502760  

• To highlight the role of exercise in patients who have completed adjuvant chemotherapy for colon cancer
• To discuss the methodology of clinical trials studying the effects of lifestyle interventions